Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Oluwayemisi Esan, Adie Viljoen & Anthony S. Wierzbicki. (2022) Colesevelam – a bile acid sequestrant for treating hypercholesterolemia and improving hyperglycemia. Expert Opinion on Pharmacotherapy 23:12, pages 1363-1370.
Read now
Read now
Linda Dayer-Berenson & Mary Finckenor. (2014) Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia. Postgraduate Medicine 126:3, pages 126-134.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Michel Farnier. (2011) Safety review of combination drugs for hyperlipidemia. Expert Opinion on Drug Safety 10:3, pages 363-371.
Read now
Read now
Peter Alagona$suffix/text()$suffix/text(). (2010) Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular Health and Risk Management 6, pages 351-362.
Read now
Read now
Adie Viljoen & Anthony S Wierzbicki. (2010) Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. Expert Review of Endocrinology & Metabolism 5:6, pages 825-834.
Read now
Read now
Ronald B Goldberg. (2009) Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective. Diabetes, Metabolic Syndrome and Obesity 2, pages 11-21.
Read now
Read now
Joel C Marrs. (2009) Colesevelam for the management of Type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 5:2, pages 187-194.
Read now
Read now
Michel Farnier. (2008) Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular Health and Risk Management 4:5, pages 991-1000.
Read now
Read now
Robert S Rosenson. (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Review of Cardiovascular Therapy 6:10, pages 1319-1330.
Read now
Read now
Theodosios Filippatos & Haralampos J Milionis. (2008) Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opinion on Investigational Drugs 17:10, pages 1599-1614.
Read now
Read now
Padmini Manghat & Anthony Wierzbicki. (2008) Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology 3:3, pages 237-255.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Harold Bays & Peter H Jones. (2007) Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vascular Health and Risk Management 3:5, pages 733-742.
Read now
Read now
Michael H Davidson. (2007) The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opinion on Pharmacotherapy 8:15, pages 2569-2578.
Read now
Read now
Articles from other publishers (26)
Zhiguo Wang & Baofeng YangZhiguo Wang & Baofeng Yang. 2022. Polypharmacology. Polypharmacology
133
198
.
Siyu Chen, Xiaoan Wen, Wenxiang Zhang, Chen Wang, Jun Liu & Chang Liu. (2016) Hypolipidemic effect of oleanolic acid is mediated by the miR‐98‐5p/PGC‐1β axis in high‐fat diet‐induced hyperlipidemic mice. The FASEB Journal 31:3, pages 1085-1096.
Crossref
Crossref
Yoshihide Yamanashi, Tappei Takada & Hiroshi Suzuki. 2017. Bile Acids in Gastroenterology. Bile Acids in Gastroenterology
61
90
.
Peter P. Toth, Dragana Nikolic, Manfredi Rizz, Jacek Rysz & Maciej Banach. 2015. Combination Therapy In Dyslipidemia. Combination Therapy In Dyslipidemia
1
10
.
Om P. Ganda & Abhimanyu Garg. 2015. Dyslipidemias. Dyslipidemias
453
463
.
Michael R. Jones & Oliseyenum M. Nwose. (2013) Role of Colesevelam in Combination Lipid-Lowering Therapy. American Journal of Cardiovascular Drugs 13:5, pages 315-323.
Crossref
Crossref
Jennifer Santee, Cameron Lindsey & Heather Pace. (2012) Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction. Journal of Pharmacy Practice 25:4, pages 447-456.
Crossref
Crossref
Carolien Out, Albert K. Groen & Gemma Brufau. (2012) Bile acid sequestrants. Current Opinion in Lipidology 23:1, pages 43-55.
Crossref
Crossref
Kate McKeage & Gillian M. Keating. (2011) Fenofibrate. Drugs 71:14, pages 1917-1946.
Crossref
Crossref
Luigi Brunetti & R. Keith Campbell. (2011) Clinical Efficacy of Colesevelam in Type 2 Diabetes Mellitus. Journal of Pharmacy Practice 24:4, pages 417-425.
Crossref
Crossref
Yehuda Handelsman & Paul S. Jellinger. (2011) Overcoming Obstacles in Risk Factor Management in Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:8, pages 613-620.
Crossref
Crossref
Luigi Brunetti & Evelyn R Hermes-DeSantis. (2010) The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus. Annals of Pharmacotherapy 44:7-8, pages 1196-1206.
Crossref
Crossref
Ross T. Tsuyuki & Craig D. Williams. (2009) Assessment of Muscle Pain Associated with Statins — A Tool for Pharmacists. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142:6, pages 280-283.
Crossref
Crossref
Prasanth N Surampudi, Prathima Nagireddy & Vivian A Fonseca. (2009) Colesevelam hydrochloride: a bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. Therapy 6:4, pages 475-487.
Crossref
Crossref
Alberto Corsini, Eberhard Windier & Michel Farnier. (2009) Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 16:1, pages 1-9.
Crossref
Crossref
Travis E. Sonnett, Terri L. Levien, Joshua J. Neumiller, Brian J. Gates & Stephen M. Setter. (2009) Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clinical Therapeutics 31:2, pages 245-259.
Crossref
Crossref
Peter H. Jones. 2009. Clinical Lipidology. Clinical Lipidology
315
325
.
John R. Guyton & Anne Carol Goldberg. 2009. Clinical Lipidology. Clinical Lipidology
281
287
.
Matthew S. Murphy & Timothy O'Brien. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
303
320
.
Dean M. Robinson & Gillian M. Keating. (2012) Colesevelam. American Journal of Cardiovascular Drugs 7:6, pages 471-483.
Crossref
Crossref
Terry A. Jacobson, Annemarie Armani, James M. McKenney & John R. Guyton. (2007) Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs. The American Journal of Cardiology 99:6, pages S47-S55.
Crossref
Crossref
Gillian M Keating & Katherine F Croom. (2007) Fenofibrate. Drugs 67:1, pages 121-153.
Crossref
Crossref
Robert H. Knopp, Christine Tsunehara, Barbara M. Retzlaff, Brian Fish, Hien Nguyen, Susan Anderson & Thuy Nguyen. (2006) Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 55:12, pages 1697-1703.
Crossref
Crossref
Sridevi Devaraj, Bryce Autret & Ishwarlal Jialal. (2006) Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia. The American Journal of Cardiology 98:5, pages 641-643.
Crossref
Crossref
William InsullJrJr. (2006) Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review. Southern Medical Journal 99:3, pages 257-273.
Crossref
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:3, pages i-xii.
Crossref
Crossref